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INTRODUCTION
Thoracic outlet syndrome (TOS) is a condition from compres-
sion of the subclavian vessels and/or brachial plexus as the 
structures travel from the thoracic outlet to the axilla.1 There is 
some general disagreement among experts on the etiology and 
pathophysiology of this condition, presumably because of the 
wide variation in symptoms that manifest in presenting pa-
tients, and also because of lack of a definitive gold standard for 
diagnosis.
Symptoms associated with TOS have traditionally been di-
vided into vascular and neurogenic causes, a distinction based 
on the underlying structures implicated. Neurogenic TOS 
(nTOS) typically presents as compression of the brachial plex-
us that primarily, but not exclusively, involves its lower trunk. 
Vascular TOS (vTOS) usually involves compression of the ves-
sel, most commonly the subclavian artery or vein, or is second-
ary to thrombus formation in the vein. Of the two, over 95% of 
all TOS patients present with nTOS.1
The thoracic outlet has three anatomic compartments: the 
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interscalene triangle, the costoclavicular, and the retropectora-
lis minor spaces.2 Of these structures, the interscalene triangle 
between the anterior and middle scalene muscles, which may 
become spasmodic or swollen, is frequently implicated.3 If 
nTOS is suspected, electrophysiological nerve studies and an-
terior scalene muscle blocks provide guidance when screening 
for patients likely to benefit from surgical decompression of 
thoracic outlet.4
Patients complaining of vague symptoms of limb fatigue, 
weakness (not definable to a particular muscle group), subjec-
tive sensory complaints, and no accepted electrodiagnostic evi-
dence demonstrative of a neural lesion are not considered to 
have true nTOS nor any other form of TOS, but should be thor-
oughly evaluated for some other disorder.5 Especially, possible 
myofascial pain and other musculoskeletal dysfunctions aris-
ing from the scalene muscles can mimic neurogenic compro-
mise of the neural structures potentially involved in TOS.
Since the scalene muscles are not a hard tissue such as a rib, 
the spasmodic or swollen scalene muscles can irritate brachial 
plexus and provoke paresthesia in upper extremity, however, it 
is less likely to damage brachial plexus to the extent that there 
are abnormal findings in electrodiagnostic test.
We recently observed a significant number of patients not 
compatible with cervical radiculopathy or true nTOS in electro-
diagnostic test, but tenderness of the scalene muscle and upper 
extremity paresthesia. Nonsurgical techniques to decompress 
the interscalene space by relaxing the scalene muscles include 
injections of anesthetic agents, steroids, and botulinum toxin.6 
Based on our clinical experience, injection of local steroids with 
local anesthesia into the anterior and middle scalene muscles 
reduces upper arm paresthesia in these patients. In these cases, 
even if the diagnosis of the patients is not true nTOS, and con-
servative treatment like steroid injection is effective in improv-
ing symptoms, unnecessary surgery can be prevented. More-
over, even if the cause of nerve irritation is spasmodic muscle, 
stretching exercise will be helpful.
To demonstrate that the injection directly affects the spas-
modic or swollen muscles, it is necessary to prove that the in-
jection would not directly block brachial plexus. Therefore, we 
hypothesized that intra-muscular steroid injection or stretching 
exercise for scalene muscles would decrease pressure on the 
brachial plexus at the interscalene triangle by relaxing the sca-
lene muscles, which would result in decreased upper extremity 
paresthesia.
A safe and accurate injection technique into the target mus-
cle has been proven using ultrasound (US) guidance.7,8 The 
purpose of this study was to compare the therapeutic effects of 
intra-muscular steroid injections into the scalene muscle un-
der US guidance on upper extremity paresthesia with those of 
stretching exercise only.
MATERIALS AND METHODS
Participants
Among patients with suspected nTOS based on clinical exami-
nation, without abnormalities in the electrodiagnostic test who 
visited the outpatient clinic of a university hospital between 
March 2013 and June 2014, and who met the following criteria 
were included in this study: 1) a main complaint of paresthesia 
in the arm, forearm, and/or hand; 2) the visual analog scale 
(VAS) greater than 4 (on a numeric scale of 0–10) for paresthe-
sia in the arm, forearm, and/or hand; 3) extreme tenderness 
over the anterior and middle scalene muscles; 4) no weakness 
in the affected site; and 5) symptoms present for at least 3 
months. Exclusion criteria included 1) prior treatment with 
botulinum toxin, lidocaine, and/or steroid injection of scalene 
muscles in the affected site; 2) prior treatment with brachial 
plexus blockade in the affected site; 3) prior scalenectomy or 
surgery for TOS in the affected site; 4) prior treatment with 
stretching exercise; 5) cervical radiculopathy or other peripher-
al nerve compression syndromes in the electrodiagnostic test; 
6) medial antebrachial cutaneous nerve conduction abnormal-
ity;9 7) previous history of adverse effect of lidocaine or steroid; 
8) presence of an unstable medical condition or a known un-
controlled systemic disease; and 9) any conditions or situations 
that might place the patient at significant risk during the study. 
Candidates with bilateral symptoms were also excluded to al-
low symptom improvement to be investigated better.
This study was approved by the Institutional Review Board 
and human subjects review committee before the study began 
(4-2014-0717). Written informed consent was obtained from all 
participants after they were briefed on the purpose and proce-
dures of the study.
Study design
The present study used a single-blind crossover design. Each 
participant completed one injection and daily exercise program 
for 2 weeks. For the purpose of the study, we compared the 
therapeutic effects between 2-weeks after one injection and 
2-weeks exercise. One physiatrist (S.C.L.), who was not blinded, 
examined all patients referred to the clinic for eligibility. The in-
vestigator (Y.W.K.) who evaluated the outcome measures was 
blinded to the group allocation throughout the study, although 
the physiatrist (S.C.L.) who performed all injections and edu-
cated exercise and the participants were not blinded.
The order of exercise and injection was randomly assigned. 
The randomization sequence for group allocation was prepared 
by a statistician who was not a co-investigator using a computer 
random number generator. After randomization, half of all pa-
tients received scalene muscle injection before exercise, while 
the order was reversed for the other patients. To avoid carry-
over effects from the previous treatment, each treatment was 
separated by a one-week rest. The study design is depicted in 
Fig. 1. Patients were not allowed to take any oral pain-related 
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medicine, engage in physical therapy, or use any intervention 
except posture correction beginning 2 weeks before and during 
the study.
US-guided injection
With the patient lying supine, a rolled towel was placed below 
the neck, and the head was rotated approximately 60º opposite 
to the injection site, exposing the region of scalene and sterno-
cleidomastoid muscles. Patients with long hair were fitted with 
disposable head caps. We performed B-mode, real-time ultra-
sonography with sterile methods using an Accuvix V10 system 
(Samsung Medison, Seoul, Korea) interfaced with a 5- to 12-
MHz linear array transducer around the targeted muscle. A 
physiatrist with more than 7 years of experience in musculo-
skeletal ultrasonography carried out US-guided injection pro-
cedures. With color Doppler images, a preliminary assessment 
determined the location of neurovascular bundles. The Dop-
pler setting changed at the vascular level in each subject. The 
anterior and middle scalene muscles were scanned along the 
craniocaudal extension and visualized on images through the 
lower half (Fig. 2A). Then, by rotating the transducer, the long 
axis of anterior or middle scalene muscle was best visualized 
on the US image (Fig. 2B and C). Once an adequate approach 
had been identified, a mark with indelible ink was made on the 
skin, adjacent to the lateral short axis of the transducer. Ap-
proximately 1 mL of lidocaine 1% was injected subcutaneously 
at the previously marked site. The injections were performed 
under US guidance with the use of an in-plane method using a 
2.6-cm, 23-guage needle. A 0.2 to 0.4 mL volume of saline was 
injected to confirm the location of the needle tip before injec-
tion of triamcinolone. Then, 0.5 mL of 20 mg triamcinolone was 
injected into each belly of the anterior and middle scalene 
muscles away from the nerve roots of the brachial plexus.
Stretching exercise
The patients were taught to do self-exercise comprising stretch-
ing to alleviate muscle spasm and tightness, and to avoid a pos-
ture that might aggravate the symptoms. In a case of a stretch of 
the right scalene group, with the patient extended the left lateral 
was flexed and right (ipsilaterally) rotated the neck. An addi-
tional stretch could be obtained by using the left hand to pas-
sively move the head and neck further in this direction.10 Twen-
ty repetitions were performed, each one held for approximately 
15 daily for 2 weeks.
Outcome measures
Gender, age, and symptom duration were documented before 
the study commenced. Our primary outcome measure was par-
esthesia in the arm, forearm, and/or hand using a 10-cm hori-
zontal VAS, which varied from no pain (VAS 0) to worst imagin-
able pain (VAS 10).6 VAS ratings were taken just before and just 
after each treatment session. Success of treatment was defined 
as a reduction exceeding 50% in post-treatment VAS compared 
to pre-treatment, whereas treatment failure was defined as 
<50% post-treatment VAS reduction compared to pre-treat-
ment. We compared the number of patients with successful 
treatments between each group.
The sign of brachial plexus block was checked. Whether there 
were symptoms of unintended brachial plexus block was as fol-
lows: 1) partial block, in cases of mild to moderate paresthesia, 
numbness and/or weakness (focal if involving single trunk; dif-
fuse if multiple trunks), and 2) complete block, in cases of se-
Fig. 1. Visualization of the cross-over design. AB=a participant who first 
received one intra-muscular injection then did stretching exercise. BA=a 
participant who first did stretching exercise then received one intra-mus-
cular injection. At T1=just before an initial treatment, T2=2 weeks after an 
initial treatment, all participants were assessed with visual analog scale 
for upper extremity paresthesia. To avoid carry-over effects from the pre-
vious treatment, each treatment was separated by a one-week rest.
A A
B B
T1
T1
T1
T1
T2
T2
T2
T2
Injection Injection
Exercise Exercise
Fig. 2. Injection into the anterior and middle scalene muscle under ultrasound guidance. (A) Transverse image of anterior and middle scalene muscles. (B) 
Longitudinal image of anterior scalene muscle for in-plane approach. A color Doppler image showed branches of subclavian artery. A dash line indicated 
needle pathway. (C) Longitudinal image of middle scalene muscle for in-plane approach. AS, anterior scalene muscle; MS, middle scalene muscle; a 
dashed circle, brachial plexus; a dash arrow, needle pathway.
A B C
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vere diffuse numbness and/or motor deficit of the upper ex-
tremity.11 Also, frequencies and severities of adverse events and 
injection-related complications were monitored throughout 
the study.
Statistical analyses
SPSS version 21.0 software (SPSS Inc., Chicago, IL, USA) was 
used for the statistical analyses. Shapiro-Wilk test was used for 
VAS rating for determining whether or not the distribution was 
normal, and the results showed no normal distribution (p<0.05 
by the Shapiro-Wilk test). Therefore, VASs were analyzed using a 
repeated measured ANOVA. Within subject factors were treat-
ment (injection versus exercise) and time (T1 and T2). Statistical 
significance was accepted for p-values <0.05.
RESULTS
Twenty patients who met the inclusion criteria were recruited 
to participate in this single-blind, crossover study. Fourteen of 
the 20 (70%) patients were female. All patients completed the 
study without follow-up loss. The average age was 45.0±10.5 
years and average duration of symptom was 12.2±8.7 months 
(Table 1).
Repeated measures ANOVA showed a significant effect of 
both treatments [F(1,38)=510.76, p<0.01]. Also, there was a sig-
nificant interaction between time and treatment [F(1,38)= 
96.04, p<0.01]. Assessment of treatments is summarized in Ta-
ble 1. After 2 weeks, there was a significant decrease of VAS after 
treatment compared with baseline in both groups (6.90 to 2.85 
after injection and 5.65 to 4.05 after stretching exercise, p<0.01) 
(Fig. 3). These findings suggested that pain was diminished in 
each treatment; however, injection treatment resulted in more 
improvements than stretching exercise (p<0.01) (Fig. 3). VAS dif-
ference of pre- and post-injection was 4.05 and that of pre- and 
post-exercise was 3.07. The number of patients with successful 
treatment, whose post-treatment VAS was reduced by more 
than 50% compared to pre-treatment, was 18 of 20 (90.0%) after 
injection, whereas the number was 5 of 20 (25.0%) after stretch-
ing exercise.
The anterior and middle scalene muscles were reliably iden-
tified and the tip of the needle was visualized within the muscle 
belly on US images in all patients. There were no cases of intra-
vascular needle placement and no instances of infection, he-
matoma, or allergic reaction. There were no symptoms of unin-
tended brachial plexus block immediately after injection 
procedure. Nine of the 20 participants experienced focal post-
injection pain, but this pain was mild to moderate and self-lim-
ited in all and no supplementary treatment was required.
Table 1. Changes of Visual Analog Scale (VAS) Scores in Each Treatment
Patient Gender Age
Symptom
duration 
(months)
Pre-injection 
VAS
Post-injection 
VAS
Difference 
ratio
Pre-exercise
VAS
Post-exercise
VAS
Difference 
ratio
1 F 28 24 8 4 0.50 4 2 0.50
2 F 65 6 6 3 0.50 3 1 0.67
3 M 50 4 7 3 0.57 3 2 0.33
4 F 40 24 10 6 0.40 6 4 0.33
5 F 44 6 6 3 0.50 3 2 0.33
6 M 55 18 6 2 0.67 2 0 1.00
7 F 43 12 8 5 0.38 5 3 0.40
8 F 39 5 7 1 0.86 1 0 1.00
9 M 33 12 10 5 0.50 5 3 0.40
10 F 52 9 9 4 0.56 4 3 0.25
11 F 35 12 8 4 0.50 10 8 0.20
12 M 40 8 5 2 0.60 6 5 0.17
13 F 44 6 6 3 0.50 8 6 0.25
14 M 50 10 5 1 0.80 7 5 0.29
15 F 57 36 7 3 0.57 8 7 0.13
16 F 64 5 3 0 1.00 6 3 0.50
17 F 41 24 8 3 0.63 10 8 0.20
18 M 41 6 6 1 0.83 6 6 0.00
19 F 28 5 8 4 0.50 9 8 0.11
20 F 50 12 5 0 1.00 7 5 2.00
6.90±1.77 2.85±1.66* 5.65±2.58 4.05±2.56†‡
Values are mean±standard deviation. Difference ratio=(post-treatment VAS-pre-treatment VAS)/pre-treatment VAS.
*p<0.05, pre-injection VAS vs. post-injection VAS, †p<0.05, pre-exercise VAS vs. post-exercise VAS, ‡p< 0.05, post-injection VAS vs. post-injection VAS.
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DISCUSSION
This study describes a therapeutic approach for treating scalene 
muscle-generated upper extremity arm paresthesia. A compar-
ison of treatments (stretching exercise vs. intra-muscular injec-
tion) was necessary to exclude an effect of brachial plexus block 
and to determine the short-term effectiveness of intra-muscu-
lar injection on upper extremity paresthesia. We demonstrated 
that US-guided anterior and middle scalene muscle injection 
with steroid led to reduced paresthesia and to a high level of 
successful treatment at short-term follow-up of patients with 
suspected scalene muscle problems. Stretching exercise of sca-
lene muscle was also effective for upper extremity paresthesia 
although injection treatment resulted in more improvements.
The definition and acceptance of TOS is one of the greatest 
challenges in research regarding this clinical entity.12 Some pre-
vious studies used clinical criteria of TOS that are predomi-
nantly subjective, such as a history of pain and/or paresthesia 
in the upper extremity, tenderness over the brachial plexus 
above the clavicle, or a positive elevated arm stress test.1,6 This 
diagnosis based on clinical criteria is what some author referred 
to as ‘‘disputed neurogenic’’ TOS.13 The use of electrodiagnostic 
studies (e.g., medial antebrachial cutaneous nerve) provides ob-
jective evidence of TOS.12 In the present study, we enrolled sub-
jects without abnormalities in the electrodiagnostic studies. 
The results indicated that patients without abnormal electrodi-
agnostic findings can be treated with intra-muscular steroid in-
jection and/or stretching exercise without surgical therapy. Al-
though there was no abnormal finding on electrodiagnostic 
test, it can irritate brachial plexus, if the scalene muscle is spas-
modic, tense, or swollen clinically.
Of these interventions to decompress the interscalene space 
by relaxing the scalene muscle, only botulinum toxin injections 
have resulted in sustained symptom reduction as demonstrat-
ed in case reports.14 However, in previous studies, which sug-
gested steroid injection or stretching exercise is not effective on 
relieving symptoms, the definition of nTOS was not clear and 
differed widely between studies. If patients were categorized 
into with and without abnormal findings on electrodiagnostic 
studies, different results could be derived.15 Botulinum toxin in-
jections to the scalene muscles did not result in clinically or sta-
tistically significant decrease in pain, paresthesia, or dysfunc-
tion in a population of subjects with TOS, while other authors 
have described positive treatment effects of botulinum toxin 
injections for patients with TOS.6,15-17 These studies also did not 
take into account the electrodiagnostic severity; such a consid-
eration may have yielded different results.
In the current study, improvement in the exercise group 
shows that the effect of injection was not due to blocking of the 
brachial plexus. A 0.5 mL volume of 20 mg triamcinolone with-
out local anesthesia was injected into each of the belly of the 
anterior and middle scalene muscles away from the nerve roots 
of the brachial plexus. Relief from less than 2 mL of local anes-
thesia for scalene muscle injections in patients with nTOS is not 
related to blockade of the brachial plexus.11 Considering the 
muscle relaxation effect of botulinum toxin, the previous stud-
ies using botulinum toxin injection also supported that the ef-
fect of injection is not by blocking the nerve but by action on 
scalene muscles.
The exact mechanism provoking scalene muscle upper ex-
tremity pain and paresthesia is unclear and may be most likely 
multifaceted. The actions of the scalene muscles include flex-
ion of the cervical spine when the scalene muscles contract bi-
laterally and lateral flexion of the cervical spine when the mus-
cles act unilaterally.18 In some cases without obvious structural 
anomalies at the time of surgery, tonic contraction of the sca-
lene muscles may produce sufficient compression at the inter-
scalene triangle to produce clinical symptoms.3 Spasmodic, 
swollen, or tense muscle, or myofascial trigger points of the 
scalenes due to prolonged tonic contraction tend to produce 
restricted lateral flexion and/or ipsilateral rotation of the neck, 
entrapment of brachial plexus.
One of scalene muscle dysfunctions is myofascial pain syn-
drome often resulting from or being perpetuated by acute or 
chronic overuse of the muscles (e.g., coughing, labored breath-
ing, especially due to chronic obstructive respiratory disease) 
or motor vehicle accidents.10 However, pathological conditions 
of the scalene muscles cannot fully be explained by myofascial 
pain syndrome alone. Injection methods in the current study 
was not a trigger point injection for myofascial pain syndrome, 
because we did not use repeated needling technique and ob-
serve any local twitch responses. Muscle fibrosis is the most 
prominent histologic finding upon examination of scalene 
muscles in nTOS patients, and the proportion of scar tissue 
present is three times greater than controls.3,19 However, this 
was the only surgical finding on true nTOS, and was not com-
patible with the findings of our patients without abnormal elec-
trodiagnostic study. Chronic muscle strain or injury triggered 
by repetitive activities and cumulative overwork can lead to 
scalene muscle dysfunction. Considering the anti-inflammato-
ry action of steroids, steroid injection might be effective in pa-
Fig. 3. Effect of each treatment. Visual analog scale (VAS) changed signif-
icantly after injection and exercise (p<0.01), and VAS after injection de-
creased more compared to that after exercise (p<0.01).
6.90
4.05
2.85
5.65
T1 T2
Injection Exercise8.00
7.00
6.00
5.00
4.00
3.00
2.00
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tients with chronic muscle strain.20 In a previous study regard-
ing piriformis syndrome, it was reported that local anesthetic 
and steroid injections may break the pain and muscle spasm 
cycle in patients who do not respond to conservative therapy.21 
In addition to the effect on inflammation, corticosteroids have 
also been reported to have a direct stabilizing effect on neural 
membranes and inhibit C-fiber transmission, thereby reducing 
ectopic discharges from neural fibers.22 This could help explain 
how corticosteroids might have antinociceptive effects even in 
non-inflammatory conditions such as tendinosis. Even though 
exact mechanism of steroid is unknown our present results, in-
dicate that upper extremity pain or paresthesia, at least without 
abnormal electrodiagnostic findings, can be treated with intra-
muscular injection.
Limitations in our study include the small number of partici-
pants and the short-term period of follow-up. The long-term ef-
fect of intra-muscular steroid injection and stretching exercise 
remains to be determined. However, the objective of this study 
was to verify that the effect of steroid injection into a scalene 
muscle is direct on the muscle itself, but not by brachial plexus 
block, and not focused to find the long-term efficacy of intra-
muscular injection or stretching exercise.
One of scalene muscle dysfunctions is myofascial pain syn-
drome, often resulting from or being perpetuated by acute or 
chronic overuse of the muscles. Although we did not observe 
local twitch responses during injection of scalene muscles, it 
cannot rule out the therapeutic effects of dry needling on upper 
extremity paresthesia.
US-guided anterior and middle scalene muscle injection 
with steroid or stretching exercise of these muscles led to re-
duced upper extremity paresthesia, although injection treat-
ment resulted in more improvement. The results suggest that 
there might be symptom relief conferred by injection into the 
muscle alone, not related to blockade of the brachial plexus. 
Nevertheless of some limitations, intra-muscular injection and 
stretching exercise of scalene muscles may offer a valuable 
therapeutic option for a selected group of upper arm paresthe-
sia patients who present with localized tenderness in the sca-
lene muscle without electrodiagnostic abnormalities.
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